Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.

Indicators

Immunic CSO hails "great" progress with MS program

By: News Direct

October 24, 2023 at 07:51 AM EDT

--News Direct--

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in forms of multiple sclerosis (MS) not characterised by relapses and saying that for Immunic, the most important was the focus on biomarkers.

Shortly ahead of the conference Immunic had disclosed interim data from their phase two clinical study on progressive MS, revealing a significant decrease in neurofilament light chain compared to a placebo. Additionally, the company presented data from a phase two study in Relapsing Multiple Sclerosis (RMS), indicating promising results with only a 5.8% confirmed disability worsening rate.

She concludes by saying that the company's MS program is going "great" overall, and expresses optimism about the direction of the company's research, emphasising the connection between their preclinical work and promising clinical trials outcomes.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-cso-hails-great-progress-with-ms-program-576781503

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security. All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.
Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.